Search results for "Chains"

showing 10 items of 257 documents

Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury.

2010

The role of the endothelial contractile apparatus in the process of brain edema formation after brain trauma is not characterized. Phosphorylation of myosin light chains by myosin light chain kinases (MLCK) activates endothelial contractile elements and results in a rearrangement of the cytoskeleton. This may enhance post-traumatic blood-brain barrier dysfunction. In order to investigate the role of the MLCK on brain edema formation and blood-brain barrier permeability after brain injury, mice were anesthetized and subjected to a controlled cortical impact (CCI). MLCK expression is significantly up-regulated after CCI with a maximum 12 h post-injury. Specific inhibition of MLCK by ML-7 resu…

MaleMyosin light-chain kinaseMyosin Light ChainsTime FactorsEndotheliumIntracranial PressureTraumatic brain injuryCentral nervous systemBrain Edemamacromolecular substancesBrain damageNaphthalenesBlood–brain barrierBiochemistryNeuroprotectionDrug Administration ScheduleFunctional LateralityStatistics NonparametricCerebral edemaCellular and Molecular NeuroscienceMicemedicineAnimalsEnzyme InhibitorsMyosin-Light-Chain KinaseNeurologic Examinationbusiness.industryAzepinesmedicine.diseaseConstrictionCell biologyMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureGene Expression RegulationBlood-Brain BarrierBrain Injuriesmedicine.symptombusinessNeuroscienceEvans BlueJournal of neurochemistry
researchProduct

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2014

Abstract Background We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy. Methods Cost-effectiveness analysis performed according to data from the available published literature. The target population was composed of untreated Caucasian patients, aged 50 years, with genotype 1 chronic hepatitis C, and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian Nati…

MaleNational Health ProgramsCost effectivenessCost-Benefit AnalysisHepacivirusNational Health ProgramHepacivirusPharmacologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundQuality-Adjusted Life YearMedicineSettore SECS-S/05 - Statistica SocialeMultivariate AnalysiBoceprevirSettore MED/12 - GastroenterologiabiologyMedicine (all)GastroenterologyMiddle AgedRecombinant ProteinMarkov ChainsRecombinant ProteinsModels EconomicTreatment OutcomeItalyDrug Therapy CombinationFemaleQuality-Adjusted Life YearsSettore SECS-S/01 - StatisticaViral loadHumanmedicine.medical_specialtyGenotypeProlineAlpha interferonInterferon alpha-2Antiviral AgentsInternal medicineBoceprevirRibavirinHumansCost-Benefit AnalysiAntiviral AgentHepaciviruPeg-interferonHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C ChronicMarkov Chainbiology.organism_classificationQuality-adjusted life yearchemistryCost-effectiveneMultivariate AnalysisQuality of LifeCost-effectivenessbusiness
researchProduct

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

2013

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for …

MaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCost effectivenessCost-Benefit AnalysisSettore MED/12 - GASTROENTEROLOGIAAged; Antineoplastic Agents; Carcinoma Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life YearsAntineoplastic AgentsKaplan-Meier EstimateDrug CostsInternal medicinemedicineHumansProspective StudiesProspective cohort studyneoplasmsSurvival rateAgedHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsCarcinomaHepatocellular carcinoma sorafenib ICER cost-effectivenessHepatocellularSorafenibmedicine.diseaseMarkov Chainsdigestive system diseasesSurgeryQuality-adjusted life yearHepatocellular carcinomaMultivariate AnalysisQuality-Adjusted Life YearsbusinessLiver cancermedicine.drugHepatology
researchProduct

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-s…

2010

Abstract Background The objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting. Methods A Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared …

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyGuanineLung NeoplasmsCost-Benefit AnalysisPopulationDocetaxelPemetrexedlcsh:RC254-282Disease-Free SurvivalGlutamatesSurgical oncologyCarcinoma Non-Small-Cell LungCell Line TumorInternal medicineGeneticsCarcinomamedicineHumanseducationLung cancerneoplasmseducation.field_of_studybusiness.industryCarcinomaHistologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMarkov Chainsrespiratory tract diseasesQuality-adjusted life yearTreatment OutcomePemetrexedOncologyDocetaxelSpainDisease ProgressionQuality of LifeFemaleTaxoidsQuality-Adjusted Life YearsbusinessResearch Articlemedicine.drugBMC Cancer
researchProduct

Liver failure caused by light chain deposition disease associated with multiple myeloma.

2012

Acute liver failure is an unusual complication in multiple myeloma. Here, we report a case of multiple myeloma with light chain deposition disease (LCDD) that presented with progressive jaundice due to intrahepatic cholestasis. Diagnosis was made after liver biopsy that showed deposition of kappa light chains occupying perisinusoidal spaces. The patient developed encephalopathy and liver failure and died despite prompt initiation of dexamethasone therapy. The current prognosis of multiple myeloma patients with liver failure due to LCDD is dismal. New therapeutic strategies might improve this condition.

MalePathologymedicine.medical_specialtyEncephalopathyParaproteinemiasCholestasis IntrahepaticImmunoglobulin light chainLight chain deposition diseaseImmunoglobulin kappa-ChainsFatal OutcomeCholestasisInternal MedicineMedicineHumansMultiple myelomaAgedAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineJaundiceLiver Failure Acutemedicine.diseaseLiver biopsyHepatic Encephalopathymedicine.symptomComplicationbusinessMultiple MyelomaInternal medicine (Tokyo, Japan)
researchProduct

Pathogenesis of Paraneoplastic Follicular Hyperkeratotic Spicules in Multiple Myeloma

1990

• We describe a 62-year-old man with multiple myeloma who developed horny spicules on his face, particularly on his nose. IgG-λ monoclonal gammopathy was detected, and the serum dysprotein was shown to be a cryoglobulin, which forms a cryogel at low temperatures. Light and electron microscopic and immunohistochemical examinations showed an intercellular precipitation and massive accumulation of the IgG dysprotein and cryoglobulin between the keratinocytes of the upper epidermis and the infundibular epithelium. The follicles were dilated and filled with parakeratotic cells, the protein deposits between them and a rudimentary hair thus resulting in the clinically visible symptoms of horny spi…

MalePathologymedicine.medical_specialtyFluorescent Antibody TechniqueDermatologyBiologyPathogenesisCryoglobulinImmunoglobulin lambda-ChainsHypergammaglobulinemiamedicineHumansMultiple myelomaEpidermis (botany)KeratosisGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryCryoglobulinemiaEpitheliumMicroscopy Electronmedicine.anatomical_structureCryoglobulinemiaImmunoglobulin GImmunohistochemistryBody regionMultiple MyelomaFacial DermatosesHairArchives of Dermatology
researchProduct

Clinicopathological and Immunohistochemical Study of Oral Amalgam Pigmentation

2012

Amalgam tattoo, the most common exogenous oral pigmentation, can sometimes be confused with melanotic lesions, being then biopsied. We present the clinicopathological characteristics of 6 biopsied cases (5 females and 1 male) of oral amalgam pigmentation. The most common location was the gingival mucosa, followed by the buccal and palatal mucosa. Morphology and distribution (stromal, perivascular, perineural, endomysial) of pigmentation was variable; there was only 1 case with fibrous capsular reaction and likewise only a single case of granulomatous foreign body reaction. Morphological variability is conditioned by the timing and amount of the pigment deposit, which is often associated wit…

MalePathologymedicine.medical_specialtyStromal cellBiopsyGingivaAntigens Differentiation MyelomonocyticHLA-DR alpha-ChainsDental AmalgamMelanosisDiagnosis DifferentialPhagocytosisAntigens CDMetals HeavyBiopsymedicineHumansMast CellsPigmentation disorderGranulomabiologymedicine.diagnostic_testCD117business.industryForeign-Body ReactionMacrophagesAmalgam tattooMouth MucosaGeneral MedicineBuccal administrationMiddle Agedmedicine.diseaseMelanosisCorrosionProto-Oncogene Proteins c-kitstomatognathic diseasesGranulomabiology.proteinFemaleMetallothioneinMicroscopy PolarizationbusinessPigmentation DisordersActa Otorrinolaringologica (English Edition)
researchProduct

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Anal…

2021

T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. We retrospectively genotyped HLA-DPB1 in 3523 patients transplanted in Germany between 2000 and 2014 and in their unrelated donors using an Illumina amplicon-NGS based assay. Aim of the study was to evaluate DP-compatibility beyond the established TCE3 algorithm by assessing the combined effect of several DP-mismatch parameters on post-transplant outcome. We implemented an extended DP-mismatch assessment model where TCE3, DP allotype expression w…

MalePermissivenessOncologyGraft vs host diseaseEpitopes T-LymphocyteGraft vs Host DiseaseKaplan-Meier Estimategraft-versus-host-disease0302 clinical medicineGermanyImmunology and AllergyChild3' Untranslated RegionsHLA-DP beta-ChainsBone Marrow TransplantationOriginal Research0303 health sciencesHistocompatibility TestingIncidenceStem cell transplantationMiddle AgedAllograftsAllotype3. Good healthHLA-DPB1Child PreschoolHistocompatibility030220 oncology & carcinogenesisFemaleUnrelated Donorslcsh:Immunologic diseases. AllergyAdultRiskmedicine.medical_specialtyAdolescentImmunologyGraft vs Leukemia EffectHuman leukocyte antigenPolymorphism Single Nucleotidestem cell transplantationRelapse free survivalLymphocyte DepletionYoung Adult03 medical and health sciencesInternal medicinemedicineHumansTransplantat-Wirt-Reaktionddc:610PermissivePeriphere StammzellentransplantationAllelesAgedRetrospective Studies030304 developmental biologyPeripheral Blood Stem Cell TransplantationHLA-DPB1Donor selectionbusiness.industryInfant NewbornModels ImmunologicalInfantmedicine.diseaseGraft-versus-host diseaseHLA-DPB1-permissivenessHLA-DPB1 expressionlcsh:RC581-607businessFrontiers in Immunology
researchProduct

Compliance and Pulse Wave Velocity Assessed by MRI Detect Early Aortic Impairment in Young Patients With Mutation of the Smooth Muscle Myosin Heavy C…

2008

Purpose To evaluate aortic elasticity with MRI on young asymptomatic individuals with mutation of the smooth muscle myosin heavy chain in whom aortic enlargement is not present. Materials and Methods Aortic compliance, aortic distensibility, and pulse wave velocity (PWV) were semiautomatically measured from MRI in 8 asymptomatic subjects having a mutation of the MYH11 gene (M+) and 21 nonmutated relatives (M−) of similar age, sex, and blood pressure characteristics. Results Despite a similar aortic diameter in both groups, the aortic compliance and distensibility were significantly lower in M+ subjects compared with M− (0.84 ± 0.33 versus 2.03 ± 0.54 mm2/mmHg, 1.18 ± 0.62 10−3 versus 5.11 ±…

MalePulsatile flow030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging0302 clinical medicinemagnetic resonance imaginggeneticsPulse wave velocityComputingMilieux_MISCELLANEOUSmedicine.diagnostic_test[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingPrognosisPulsatile FlowAortic valve stenosiscardiovascular systemCardiologyElasticity Imaging TechniquesFemalemedicine.symptomAlgorithmsBlood Flow VelocityAdultmedicine.medical_specialtypulse wave velocityAortic Valve InsufficiencySensitivity and SpecificityAsymptomaticYoung Adult03 medical and health sciencesElastic Modulusmedicine.arteryInternal medicineImage Interpretation Computer-Assistedmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansGenetic Predisposition to DiseaseRadiology Nuclear Medicine and imagingAortaMyosin Heavy ChainsReceiver operating characteristicbusiness.industryReproducibility of ResultsMagnetic resonance imagingAortic Valve StenosisImage Enhancementmedicine.diseaseaortaBlood pressureMutationelasticitybusiness
researchProduct

Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA‐DR and DQ allele frequency

2007

OBJECTIVE: To investigate the relationship of the polymorphic enhancer HS1,2 central to the 3' enhancer complex regulatory region (IgH3'EC) of the immunoglobulin heavy chain genes with systemic sclerosis (SSc) disease and compare it with HLA-DR and DQ associations. METHODS: A total of 116 patients with SSc were classified as diffuse (dSSc) or limited (lSSc), and as carriers of antitopoisomerase I (anti-Scl70) or anticentromere (ACA) antibodies. Allele and genotype frequencies were assessed in the population as a whole and in the two major subsets, dSSc and lSSc. The concentration of peripheral blood immunoglobulin levels was also determined and analysed according to the genotypes. RESULTS: …

MaleSettore MED/16 - REUMATOLOGIAsystemic sclerosisclinical evaluationgenotype phenotype correlationHLA DR antigenSclerodermaGene FrequencyGenotypeImmunology and Allergycentromere antibody; HLA DR antigen; immunoglobulin enhancer binding protein; scl 70 antibody; adult; aged; article; clinical evaluation; controlled study; DNA polymorphism; female; gene frequency; genotype phenotype correlation; human; major clinical study; male; priority journal; risk factor; systemic sclerosis; Adult; Aged; Autoantibodies; Enhancer Elements (Genetics); Esophagus; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; HLA-DQ Antigens; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Phenotype; Polymorphism Genetic; Scleroderma Systemic; Statistics Nonparametric; Stomacheducation.field_of_studycentromere antibodyStatisticsStomacharticleMiddle AgedExtended Reportimmunoglobulin enhancer binding proteinEnhancer Elements GeneticPhenotypepriority journalrisk factorFemaleImmunoglobulin Heavy ChainsAdultGenotypeImmunologyPopulationBiologyGeneral Biochemistry Genetics and Molecular BiologyStatistics NonparametricEsophagusGeneticRheumatologyHLA-DQ AntigensHLA-DRHumanscontrolled studyEnhancer Elements (Genetics)NonparametricGenetic Predisposition to DiseasehumanPolymorphismAlleleeducationEnhancerAllele frequencyAgedAutoantibodiesscl 70 antibodyPolymorphism GeneticScleroderma SystemicSystemicHLA-DR Antigensmajor clinical studyGenotype frequencySettore BIO/18 - GeneticaDNA polymorphismImmunologyImmunoglobulin heavy chain
researchProduct